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Abstract. – OBJECTIVE: To provide informa-
tion on the clinical presentation of sciatic neu-
ropathy and its management in a real-world set-
ting, and to analyze the effects of a multimodal 
approach based on the association of physical 
and pharmacological therapy. 
PATIENTS AND METHODS: A multicentric ob-
servational prospective study was conducted in 
44 Italian tertiary centers specialized in Physical 
Medicine and Rehabilitation, Orthopedics, Neu-
rology, Neurosurgery, and Rheumatology. To de-
velop a shared management of LPB with sciat-
ica, a dedicated clinical record was proposed 
to collect data about diagnosis, treatment, and 
outcomes. Pain, disability, and quality of life 
were recorded trough validated questionnaires 
at baseline and after a two-month follow-up. 
RESULTS: 394 patients (age, mean ± SD 55.7 ± 
14.1 years, 57.1% females) with chronic LBP and 
sciatica were enrolled in the study. The charac-
teristics of the selected group showed a certain 
variability in the clinical presentation. At base-
line, patients received several different thera-
peutic options among physical, pharmacolog-
ical and neurotrophic treatments. A subgroup 
of 312 patients was treated with a combination 
of neurotrophic agents containing alpha-lipoic 
acid (ALA). After a two-month follow-up, a gen-
eral improvement in both perceived pain and 
functional disabilities was observed. A signifi-
cant improvement (p < 0.001) in the Pain Numer-
ic Rating Scale (NRS), Roland e Morris Disability 
Questionnaire (RMDQ) and Brief Pain Inventory 
(BPI) Italian short version was observed. 
CONCLUSIONS: Sciatic neuropathy is a multi-
faceted condition managed by means of a wide 
spectrum of therapeutic options. The results of 
this study suggest that a multimodal approach 
based on the association of ALA with physical 
and pharmacological therapies can be benefi-
cial in the treatment of LBP with sciatica.
Key Words:
Mesh terms) low back pain, Sciatic neuropathy, 
Complementary therapies, Pain management, Al-
pha-lipoic acid. 
Introduction
Chronic low back pain (LBP) with sciatica is 
defined as pain and discomfort, localized below 
the costal margin and above the inferior gluteal 
folds, with referred leg pain persisting for at least 
12 weeks1-5.
Sciatic neuropathy is among the most com-
mon peripheral neuropathies, since it is es-
timated to affect 5 in every 10000 Western 
adults6. Thus, it represents a social problem 
both in terms of patients’ suffering and health 
costs for treating the progression of the dis-
ease. More generally speaking, LBP of at least 
moderate intensity and duration has an annual 
incidence in the adult population of 10-15% and 
a prevalence of 15-30%. It becomes increas-
ingly frequent in patients older than 65 years. 
Therefore, a relevant number of elderly people, 
approximately one out of every three to four, 
suffers from low back pain3.
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Chronic LBP with sciatica shows a broad range 
of clinical manifestations and consequences on 
patients’ lives, from a preserved functionality 
in spite of pain to a severe disability or an inter-
ference with sleep by persistent back pain and 
radicular pain and paresthesia1-5. Chronic LBP 
with sciatica is a quite common cause of long-
term disability in middle-aged people and, due 
to its resistance to pharmacological and surgical 
interventions, requires a multimodal and multi-
disciplinary approach1,5,7. 
The economic burden of chronic LBP, in gen-
eral, is relevant, spine diseases being fifth in 
terms of hospitalization/inpatients costs and first 
as a cause of absenteeism and burden of disabil-
ity8.
The optimal management of chronic LBP with 
sciatica is still a matter of debate. A large panel 
of therapeutic options is available5,9-12. 
Surgery doesn’t seem to be a first choice treat-
ment for radicular neuropathy, except the cases 
in which it can’t be avoided. A systematic review 
with meta-analysis of cohort studies revealed that 
patients with sciatica still experience pain and 
disability 5 years after surgery7.
Non-pharmacologic therapies for chronic LBP 
with sciatic neuropathy include acupuncture, ex-
ercise therapy, massage therapy, yoga, cognitive 
behavioral therapy or progressive relaxation, spi-
nal manipulation, and intensive interdisciplinary 
rehabilitation. Although the level of supporting 
evidence for the different therapies varies from 
fair to good, at the moment there is no consensus 
about a first choice treatment9-11.
Notably, recent evidence suggests that a multi-
modal and multidisciplinary approach involving 
orthopedics, physiatrists, rheumatologists, and 
neurologists may be the most appropriate for 
sciatic neuropathy. That approach also implies 
a detailed knowledge of pathophysiological and 
clinical data in order to obtain a 360-degree 
framework of the condition and to address the 
priority needs in its management.
This study focused on patients with chronic 
LBP with sciatica, is part of a wider project aimed 
at proposing an appropriate and shared manage-
ment at a national level of all patients with periph-
eral compression neuropathy (e.g. carpal tunnel 
syndrome and sciatic neuropathy)12. Thus, the 
Management of Peripheral Neuropathies Study 
Group, composed of Specialists in Physical and 
Rehabilitation Medicine, Orthopaedics, Neurolo-
gy, Neurosurgery, Rheumatology, Anesthesiolo-
gy and Pain Medicine, has designed (March-May 
2012) and conducted for the following 14 months 
(May 2012-June 2013) this observational study 
aimed at providing an updated picture of chronic 
LBP with sciatica, including the clinical charac-
teristics of the patients (etiology, location, sever-
ity, duration) and the management of the disease. 
Participating centers were outpatients care ser-
vices in hospitals or in centers for outpatients 
care, both public or private, spread throughout 
Italy. 
To develop a shared management of LPB with 
sciatica, a dedicated clinical record was proposed 
to collect data about diagnosis, treatment, and 
outcomes.
The main objectives were to determine the 
clinical and demographic characteristics of pa-
tients, the concomitant diseases and the response 
to the multimodal treatment proposed.
As regards diagnosis, we included in the clin-
ical report the etiology, location, clinical charac-
teristics of the disease, a complete physical exam-
ination including Lasegue’s and Wassermann’s 
maneuvers and osteotendinous reflexes, in order 
to propose a single shared protocol for the diag-
nosis of the compression neuropathy.
Previous diagnostic procedures, previous and 
ongoing treatments (physical therapy, pharmaco-
logical therapy or neurotrophic agents) were also 
included in the clinical report. 
The Study Group decided to recommend the 
use of neurotrophic agents, and in particular of 
alpha-lipoic acid (ALA), because of the increas-
ing evidence of effectiveness in neuropathic pain 
and considering the good tolerability of the treat-
ment12-25. 
ALA is an antioxidant that has been recently 
identified as a first-choice treatment for chronic 
neuropathic pain13, because of the proven effec-
tiveness compared to placebo in the treatment of 
neuropathic pain13-22. 
ALA exerts a protective effect on the nerve 
fibers, acting on the nerve inflammation and 
the progression of nerve damage. Furthermore, 
it does not interfere with other pharmacological 
treatments and is generally well tolerated21, so 
we decided to recommend its use as an adjuvant 
for the treatment of neuropathy in the patients 
enrolled in the study.
The study group recommended a multimodal 
treatment, including physical, pharmacological 
and neurotrophic therapies, but decided not to 
give a precise indication about which treatment 
to select within the various options. This decision 
was taken in order to observe the current man-
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agement of sciatic pain in a real world setting.
At the same time, the study was designed to 
provide a feedback on the efficacy of current 
clinical practice and of the multimodal approach 
proposed, through the registration of clinical da-
ta at baseline and at the end of the follow-up. 
The Study Group selected the parameters to be 
evaluated and the questionnaires to be adminis-
tered on the basis of the international literature. 
Among the questionnaires, the Numeric Rating 
Scale (NRS)26,27 was adopted by Pain in Europe 
(http://www.paineurope.com), the European sur-
vey about chronic pain; the Roland and Morris 
Disability Questionnaire (RMDQ)28,29 is aimed 
at evaluating disability; the Brief Pain Invento-
ry-short form (BPI)30,31 is focused on measuring 
pain and its interference on activities of daily liv-
ing; the Short Form-12 Health Survey (SF-12)32-34 
is used to evaluate the quality of life.
Patients and Methods
Study Design 
The observational study was carried out be-
tween May 2012 and June 2013, enrolling 394 
consecutive patients with chronic LBP with sci-
atica followed in 44 specialized Italian centers 
participating in the Management of Peripheral 
Neuropathies Study Group (see the list of partic-
ipating centers). 
The main objectives were to determine (i) the 
pattern of this condition; (ii) the concomitant dis-
eases and the characteristics of patients; (iii) the 
response to treatments.
Patients of both genders older than 18 years 
with chronic (>12-week duration) LBP with sciat-
ica were included. 
A model of dedicated clinical record was devel-
oped to homogeneously collect the most relevant 
data about diagnosis, monitoring, and outcomes.
The study was conducted in accordance with 
the current guidelines of good clinical practice 
(GCP) regulations relating to clinical trials and 
the Declaration of Helsinki and was approved by 
the local Ethics Committee. 
Informed consent was obtained from all the 
patients after explaining the aim of the work and 
the relevance of the questionnaires.
Data Collection
At baseline, the following information was col-
lected: demographic data (age, gender, anthropo-
metric data); lifestyle and work activity and their 
relation to the condition; referral from general 
practitioners (GP) or specialists; comorbidities; 
aetiology, location, and clinical characteristics of 
the compression neuropathy; complete physical 
examination including Lasegue’s and Wasser-
mann’s maneuvers and osteotendinous reflexes; 
previous diagnostic procedures, previous and on-
going treatments (physical therapy, pharmaco-
logical therapy, or neurotrophic agents used for at 
least 10 days consecutively). 
Patients were asked to state if they considered 
the previous treatments effective or not. 
Pain Assessment
The pain was assessed by means of stand-
ardized questionnaires whose Italian translations 
have been previously validated: the NRS, the 
RMDQ, the Italian version of the BPI, and the 
SF-12 questionnaire.
The NRS26,27 is a segmented numeric horizon-
tal bar on which patients select a whole number 
(from 0 “no pain” to 10 “worst possible pain”) 
that best reflects the intensity of their pain at rest 
and on movement. It has become a widely used 
instrument for pain screening and is ubiquitous 
as a screener in many health care environments. 
The RMDQ28,29 is a patient-reported measure 
of back pain which explore the patients’ ability 
to perform 24 activities of daily living. Items 
are scored to yield a total score from 0 “no disa-
bility” to 24 “maximum disability”. It is used to 
assess the patients’ subjective rating of perceived 
disability and helps the clinician to address the 
functional limitations of the patients. Scores were 
categorized as follows:
• From 0 to 9: sub-acute or chronic LBP with 
mild disability (may be managed by the gener-
al practitioner);
• From 10 to 13: sub-acute or chronic LBP with 
a moderate disability;
• > 14: sub-acute or chronic LBP with severe 
disability (a multimodal and multidisciplinary 
management is needed). 
The BPI30 is a self-administered assessment 
tool which measures pain interference. It consists 
of 9 items measuring interference, experience of 
pain on the current day, and localization of pain 
occurrence. Scores are assigned on a scale from 
0 “does not interfere” to 10 “completely inter-
feres”. Its short form31 is used for clinical trials 
and translated in foreign languages, as in the case 
of the short Italian version named BQVD, Breve 
Questionario per la Valutazione del Dolore). 
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Scores were categorized as follows:
• Factor 1 – Pain intensity (range 0-50);
• Factor 2 – Affective interference (range 0-30);
• Factor 3 – Activity interference (range 0-30).
The SF-1232-34 is a generic health status meas-
ure including 12 items which yield a profile of 
functional health and well-being. It is recom-
mended for self-administration, brevity, simplici-
ty, validity and reliability.
Statistical Analysis
Quantitative variables were reported as mean 
± standard deviation (SD) and range, qualitative 
variables as absolute and relative frequencies. 
Data were summarized in tables and figures as 
appropriate.
The data collected were analyzed by standard 
descriptive statistics.
The intragroup differences in NRS, RMDQ, 
BPI (baseline vs. end of follow-up) were assessed 
by means of paired t-test. Differences have been 
considered significant where p < 0.05. 
As regards the SF-12, we only reported the 
variation of the answers to each item, so as to 
point out which ones were more influenced by 
the treatments. 
No direct comparison of the treatments was 
performed.
No missing data have been replaced and no 
replacement policy has been implemented; as a 
matter of fact, the analysis fully reflects the ob-
served values. 
The statistical analysis has been performed 
using the software SPSS Statistical Package, ver-
sion 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients 
Baseline characteristics of the 394 patients (age, 
mean ± SD 55.7 ± 14.1 years, 57.1% females) with 
chronic LBP with sciatica enrolled in the study 
are reported in Table I. Among all patients, 12.4% 
were menopausal and 2% pregnant women.
For the majority of patients (63.5%) time 
since the initial diagnosis ranged from 3 to 12 
months, while for the others initial diagnosis was 
made more than one year before enrolment. The 
most common comorbidities were osteoarthritis 
(28.2%), diabetes (19.3%), osteoporosis (17%), 
thyroid disorders (10.9%) and rheumatoid arthri-
tis (3.6%). 
Physical Examination
Following physical examination, patients were 
classified as having: sciatica (82.7%, n = 326), 
low back pain (9.4%, n = 37), cruralgia (3.6%, n = 
14). The diagnosis after the physical examination 
was missing in 17 (4.3%) patients.
As regards semiotic maneuvers a positivity in 
Lasègue’s test was observed in 68.8% of patients, 
and a positivity in Wassermann’s test in 30.2% 
of patients. Osteotendinous reflexes were normal 
in 47.2%, reduced in 36.3%, absent in 3.5% of 
patients. Muscle wasting was observed in 26.7% 
of patients.
49.7% of patients reported diurnal paresthesia 
and 45.9% reported nocturnal paresthesia. 
Instrumental Diagnostic Procedures
Considering diagnostic imaging, 52.3% (n = 
206) of patients underwent conventional X-ray, 
Table I. Demographic and clinical characteristics of patients 
at baseline.
 All patients 
 (N = 394)
Gender no. (%)
 - Female 225 (57.1%)
 - Male 169 (42.9%)
Age (years)  55.7 ± 14.1
mean ± SD (range)  (25-87)
Body weight (kg)  73.4 ± 12.9
mean ± SD (range) (47-120)
Height (cm)  168.7 ± 8.5
mean ± SD (range) (140-197)
BMI (kg/m2) 26.1 ± 4.2
mean ± SD (range) (17.9-43.8)
BMI categories (reference values) no. (%)
 - Underweight (< 18.5 kg/m2) 2 (0.5%)
 - Normal weight (18.5-24.9 kg/m2) 165 (41.9%)
 - Overweight (25-29.9 kg/m2) 143 (36.3%)
 - Obesity (≥ 30 kg/m2) 62 (15.7%)
 - ND 22 (5.6%)
Smoking habit  no. (%)
 1. No 226 (57.3%)
 2. Yes 122 (31.0%)
 - ND 46 (11.7%)
Work activity no. (%) no. (%)
 1. Blue collar 59 (15.0%)
 2. White collar 103 (26.1%)
 3. Homeworker 82 (20.8%)
 4. Retiree 79 (20.1%)
 5. Others  63 (16.0%)
 - ND 8 (2.0%)
Work-related chronic back pain no. (%)
 1. No 169 (42.9%)
 2. Yes 80 (20.3%)
 3. Uncertain 106 (26.9%)
 - ND 39 (9.9%)
ND: Not determined.
Observational multicentric study on chronic sciatic pain: clinical data from 44 Italian centers
1657
57.4% (n = 226) nuclear magnetic resonance 
(NMR), and 17.5% (n = 69) computed tomogra-
phy (CT). Electromyography was performed in 
10.7% (n = 42) of patients. 
Final Diagnosis
All in all, the most prevalent conditions were 
herniated disc in 53.8% (n = 212) of patients and 
disc space narrowing in 11.9% (n = 47).
Baseline Treatments Before Enrolment
Previous treatments before enrolment had 
been prescribed by the GPs in 62.9% of pa-
tients, by a specialist in 32.5%. The response 
to previous treatments, classified in three 
main categories (physical therapy, pharma-
cological therapy, and neurotrophic therapy), 
is reported in Table II. Physical therapy in-
terventions were associated to low response 
rates (in general less than a third of patients) 
with the exclusion of corset (57.3% of respond-
ers), TENS (31.8%), laser/carbon dioxide laser 
(28.8%), and ultrasound (27.5%). Response 
rates to pharmacological therapy ranged be-
tween 39.4% and 59.5% with the different op-
tions. Among neurotrophic medications, on-
ly ALA obtained satisfactory response rates 
(64.9%). 
Prescribed Treatments
The prescribed treatments at baseline, classi-
fied in the same three main categories, are report-
ed in Table III. 
A wide variability in the interventions was ap-
parent. The most prescribed physical treatments 
were TENS (28.9%) and corsets (26.1%).
Table II. Baseline treatments before enrolment.
 Patients  Clinical response 
 treated   
 (no.)  No Yes ND
Physical therapy no. (%)    
Corset  89 25 (28.1%) 51 (57.3%) 13 (14.6%)
Laser/Carbon dioxide laser  66 34 (51.5%) 19 (28.8%) 13 (19.7%)
Electroanalgesia  36 21 (58.3%)  6 (16.7%)  9 (25.0%)
Ultrasound  51 27 (52.9%) 14 (27.5%) 10 (19.6%)
TENS  85 44 (51.8%) 27 (31.8%) 14 (16.5%)
Diadynamic  42 23 (54.8%)  7 (16.7%) 12 (28.6%)
Others   24 13 (54.2%) 8 (33.3%)  3 (12.5%)
Pharmacological therapy no. (%)    
NSAIDs 226 86 (38.1%) 97 (42.9%) 43 (19.0%)
Corticosteroids (oral)  88 19 (21.6%) 52 (59.1%) 17 (19.3%)
Corticosteroids (infiltration)  43  7 (16.3%) 19 (44.2%) 17 (39.5%)
Paracetamol  94 49 (52.1%) 37 (39.4%) 8 (8.5%)
Opioids  42  6 (14.3%) 25 (59.5%) 11 (26.2%)
Others  29 14 (48.3%) 11 (37.9%) 4 (13.8%)
Neurotrophic therapy no. (%)  
ALA  37  6 (16.2%) 24 (64.9%) 7 (18.9%)
Carnitine  46 16 (34.8%)  9 (19.6%) 21 (45.7%)
B complex vitamins  61 21 (34.4%)  9 (14.8%) 31 (50.8%)
Others   9  4 (44.4%)  4 (44.4%) 1 (11.1%)
Table III. Prescribed treatments.
 All patients
 No. (%) 
Physical therapy 
Corset 103 (26.1%)





Others  104 (26.4%)
Pharmacological therapy 
NSAIDs 135 (34.3%)
Corticosteroids (oral) 59 (15.0%)





ALAnerv ON 226 (57.4%)
ALA600 SOD 86 (21.8%)
Carnitine 27 (6.9%)
B complex vitamins 14 (3.6%)
Others 10 (2.5%)
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As regards pharmacological therapy, 
NSAIDs and paracetamol (34.3% and 25.6%, 
respectively) were more frequently used than 
corticosteroids (oral 15% and infiltration 8.4%). 
A considerable amount of cases (19%) required 
opioids.
Among neurotrophic agents, the most pre-
scribed were ALAnerv ON® (ALA 300 mg, 
gamma-linolenic acid, GLA, 180 mg, honokiol 
27 mg, selenium 25 µg, vitamin B1 1.05 mg, 
vitamin B2 1.2 mg, vitamin B5 4.5 mg, vita-
min B6 1.4 mg, vitamin E 7.5 mg, and seleni-
um 25 µg; Alfa Wassermann, Bologna, Italy) 
and ALA600 SOD® (ALA 600 mg, superoxide 
dismutase, SOD, 140 IU/day, vitamin E 7.5 
mg, and selenium 25 µg; Alfa Wassermann, 
Bologna, Italy). The associations have been 
prescribed to 57.4% and 21.8% of patients, re-
spectively. The use of carnitine or B complex 
vitamins was relatively limited, accounting for 
approximately 10%. 
At the final evaluation after a two-month fol-
low-up, the compliance to treatments and the 
need for dose changing were recorded. 
Physical therapy was completed as planned in 
65.2% of patients. 
Considering pharmacological therapy, daily 
administration schedule was unchanged in 72.1% 
of patients and withdrawn in 1.5%; while a dose 
increase was needed in 9.4% of patients, and a 
dose reduction in 4.1%. 
Considering neurotrophic therapy, daily ad-
ministration schedule was unchanged in 78.7% 
of patients and withdrawn in 2.5%; while a dose 
increase was needed in 4.1% of patients, and a 
dose reduction in 3.8%. 
An analysis of patients’ characteristics ac-
cording to the prescribed treatments is report-
ed in Table IV. The analysis focuses on the 
association of physical, pharmacological and 
neurotrophic therapies and their prescription 
according to age, gender and intensity of pain 
(mild, moderate, severe according to the NRS 
scale). We observed a good adherence to the 
recommendation of the Study Group to adopt a 
multimodal strategy, with a greater prescription 
of all the three categories of treatments (neuro-
trophic, pharmacological and physical) in the 
patients with the higher levels of pain.
Pain and Disability Scores 
At the end of the study, a general improvement 
in both perceived pain and functional disabilities 
was observed. 
Specifically, the NRS (cases assessed, baseline 
vs. end of follow-up 360 vs. 341) significantly 
improved in both pain at rest (baseline vs. end of 
follow-up, mean ± SD 6.6 ± 2.2 vs. 2.1 ± 1.8, p < 
0.001) and pain on movement (7.6 ± 1.9 vs. 2.6 ± 
1.8, p < 0.001).
NT: Neurotrophic Therapy; Phys T: Physical Therapy; Phar T: Pharmacological Therapy.
Table IV. Prescribed treatments according to patients’ characteristics and pain intensity.
                  Prescribed therapy   
      
 NO NT    NT 
 (Phys T or Phar T  NT NT + Phys T 
 or both) NT + Phys T + Phar T + Phar T Total
Patients No. 33 25 44 87 205 394
Age      
   < 65 years 24 (75.0%) 15 (60.0%) 29 (67.4%) 63 (73.3%) 149 (73.0%) 280 (71.8%)
   ≥ 65 years 8 (25.0%) 10 (40.0%) 14 (32.6%) 23 (26.7%) 55 (27.0%) 110 (28.2%)
Gender      
   - Female 17 (53.1%) 18 (72%) 23 (54.8%) 45 (51.7%) 119 (58.6%) 222 (57.1%)
   - Male 15 (46.9%) 7 (28.0%) 19 (45.2%) 42 (48.3%) 84 (41.4%) 167 (42.9%)
NRS at rest      
Mild (1-3) 2 (7.7%) 4 (16.6%) 5 (12.2%) 8 (10.1%) 7 (3.7%) 26 (7.3%)
Moderate (4-6) 9 (34.6%) 10 (41.7%) 17 (41.5%) 18 (22.8%) 67 (35.7%) 121 (33.8%)
Severe (7-10) 15 (57.7%) 10 (41.7%) 19 (46.3%) 53 (67.1%) 114 (60.6%) 211 (58.9%)
NRS on movement      
Mild (1-3) 0 (0%) 1 (4.2%) 1 (2.4%) 1 (1.2%) 7 (3.7%) 10 (2.8%)
Moderate (4-6) 1 (4.0%) 10 (41.6%) 16 (39.1%) 16 (19.8%) 35 (18.5%) 78 (21.6%)
Severe (7-10) 24 (96%) 13 (54.2%) 24 (58.5%) 64 (79.0%) 147 (77.8%) 272 (75.6%)
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The RMDQ mean proportion of positive 
responses (cases assessed 203 vs. 192) passed 
from 14.1 ± 5.5% to 5.8 ± 4.3% (p < 0.001) 
(Figure 1). For all the items a trend towards 
a reduction (ranging from –3% to –59%) was 
observed. 
An improvement in all three factors of BPI 
short Italian version was recorded (factor 1, pain 
intensity 284 ± 93 vs. 111 ± 84; factor 2, affective 
interference 150 ± 76 vs. 47 ± 57; factor 3, activity 
interference 186 ± 65 vs. 74 ± 59, p < 0.001 for all). 
Pain relief from any treatment in the last 24 hours 
was reported more frequently at the end of the 
study (39.6 ± 20.6% vs. 60.4 ± 29.2%, p < 0.001). 
An improvement in all the SF-12 items was 
observed (Table V). 
Discussion
This observational study with descriptive pur-
poses provides a “real life” representation of 
chronic LBP with sciatica in Italy, in terms of 
patients’ characteristics and therapeutic interven-
tions. 
The group of patients selected is likely repre-
sentative of the whole population suffering from 
this condition: young-elderly, the onset of signs 
and symptoms generally occurring in the last 12 
months, a broad range of causes, clinical pres-
entation and radiologic features. 
However, the presence of pain and disability 
is a quite common aspect, confirming the high 
burden on health and on quality of life of chronic 
LBP with sciatica. 
Similarly, a wide variability in the management 
of the disease is apparent. This is consistent with 
the fact that guidelines do not express homoge-
nous and straightforward recommendations9-11. 
Notably, according to the Italian Diagnostic, 
Clinical and Therapeutic pathway for patients 
with LBP35, the first level approach should in-
clude, in both acute and chronic conditions, coun-
seling, modification of daily life, and active life-
style, followed by conventional palliative medical 
treatment and rehabilitation. This latter aimed at 
functional recovery by means of several differ-
ent interventions (exercises, cognitive-behavioral 
therapy, back school and multidisciplinary treat-
ments).
Unfortunately treatment guidelines usually re-
fer to LBP with or without sciatica as a unique 
pathology. So, as the targets are both LBP and 
neuropathic sciatic pain, a multimodal strategy 
targeting both kinds of pain should be followed. 
At the moment considering the individual 
patient’s characteristics, including not only the 
symptoms but also the level of disability, is ad-
viced. Therefore, there is consensus about a mul-
timodal and multidisciplinary approach, focused 
on the pathophysiology of the disease, and more 
specifically acting on two main directories: pain 
and disability.
As far as the pharmacological treatments are 
concerned, when choosing the pharmacological 
therapy, typically anti-inflammatory and anal-
gesic medications, the average age of patients 
with chronic LBP and the even increasing prev-
alence in the older population have to be taken 
into account to prevent a higher occurrence of 
side effects and reach an acceptable harm to 
benefit ratio. To this aim, pathogenetic therapies 
represent a promising option and, accordingly, 
their prescription is recommended in neuropath-
ic pain13,14. 
A recent Post-hoc analysis of the NATHAN I 
trial, in which patients with diabetic neuropathy 
were treated with ALA 600 mg/day by oral route 
for 4 years, highlighted the significant effective-
ness of ALA in particular in older people (>65 
years), with a significant reduction in the Neurop-
athy Impairment Score (NIS) vs. placebo21. 
Among neuropathic mechanisms of sciatica 
pain, oxidative stress which develops after the 
peripheral neuropathic lesion is acknowledged 
as a relevant factor responsible for neuropathic 
pain, leading to the activation of an inflammatory 
pathway involving the whole peripheral nerve up 
to the spinal dorsal horn, and, subsequently, of 
microglia36-39. This process may result in spine 
sensitization and in chronic neuropathic pain14,38.
Recently, ALA and superoxide dismutase 
(SOD), another antioxidant agent endowed with 
Figure 1. Roland and Morris Disability Questionnaire 
(RMDQ) at baseline and at the end of treatment.
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Table V. SF-12 Health Survey Questionnaire at baseline and at the end of treatment. 
  Baseline  Final
 1. In general, would you say your health is  
 Excellent 0.6% 1.3%
 Very good 7% 23.9%
 Good 43.6% 50.3%
 Fair 31.4% 21.4%
 Poor 17.4% 3.1%
Does your health now limit you in these activities? If so, how much?  
 2. Moderate activities  
 Yes, limited a lot 61.6% 9.9%
 Yes, limited a little 34.3% 62.3%
 No, not limited at all 4.1% 27.8%
 3.	 Climbing	several	flights	of	stairs  
 Yes, limited a lot 48.3% 5.6%
 Yes, limited a little 42.4% 54.9%
 No, not limited at all 9.3% 39.5%
During the past 4 weeks, how much of the time have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health?
 4. Accomplished less than you would like
 Yes 84.8% 38.3%
 No 15.2% 61.7%
 5. Were limited in the kind	of	work	or	other	activities    
 Yes 91.2% 58%
 No  8.8% 42%
During the past 4 weeks, how much of the time have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or anxious)?
 6. Accomplished less than you would like  
 Yes 78.4% 29.4%
 No 21.6% 70.6%
 7. Did work	or	activities	less	carefully	than	usual     
 Yes 57.3% 13.9%
 No 42.7% 86.1%
 8.	 During	the	past	4	weeks,	how	much	did	pain	interfere	with	your	normal	work	(including	both	housework	and
 work outside the home)?
 Not at all 1.2% 4.4%
 A little bit 2.3% 38.1%
 Moderately 26.9% 45%
 Quite a bit 48.5% 10%
 Extremely 21.1% 2.5%
How much of the time during the past 4 weeks  
 9.		Have	you	felt	calm	and	peaceful?   
 All of the time 1.2% 12.7%
 Most of the time 15.3% 36.1%
 A good bit of the time 7.1% 20.8%
 Some of the time 45.3% 22.2%
 A little of the time 22.9% 6.3%
 None of the time 8.2% 1.9%
10.	 Did	you	have	a	lot	of	energy?  
 All of the time 1.8% 7.1%
 Most of the time 5.9% 22.4%
 A good bit of the time 5.9% 23.1%
 Some of the time 29.3% 35.2%
 A little of the time 40% 9.6%
 None of the time 17.1% 2.6%
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anti-inflammatory properties40,41, have been prov-
en effective in the management of diabetic neu-
ropathy42, low back pain43, and chronic neck 
pain44.
Therefore, antioxidant agents like ALA and 
SOD may be a useful choice in the multimodal 
treatment strategy for chronic LBP patients, since 
they can contribute to pain control due to their 
prevalently anti-inflammatory action42-44. 
The benefit of ALA in association with neuro-
trophic agents has been demonstrated in patients 
with chronic conditions characterized by an im-
pairment in the nerve fiber function. Clinical 
trials on patients with radiculopathies and carpal 
tunnel syndrome show that the combination of 
ALA and GLA, a polyunsaturated n-3 (omega-3) 
fatty acid, exerts a synergistic positive effect on 
symptoms and peripheral nerve fiber conduc-
tion19,20,24. Neurotrophic agents such as GLA, ho-
nokiol and vitamin B complex have been used in 
association with ALA to improve sensory-motor 
function12,23-25.
Antioxidant and neurotrophic agents may con-
tribute to pain control, thus allowing to reduce 
analgesic medications and, as a consequence, 
to improve the safety profile of the therapeutic 
strategy adopted. 
On the other hand, the effectiveness of physical 
therapies is controversial because of the lack of 
high quality clinical trials9-12,45,46. Transcutaneous 
electrical nerve stimulation (TENS) is based on 
the delivering of electrical stimulation to the un-
derlying nerves via electrodes placed over the in-
tact skin surface near the source of maximal pain.
Four high-quality randomised controlled trials 
(585 patients) comparing TENS with placebo for 
chronic low-back pain have been published. Due 
to conflicting evidence, it is unclear if TENS is 
beneficial in reducing back pain intensity45. 
It has to be highlighted that any intervention 
has to be considered in the framework of a multi-
disciplinary approach in order to address the 
various pathogenetic mechanisms with an appro-
priate multimodal treatment. 
On the base of these considerations, our Study 
Group decided to recommend a multimodal ap-
proach including pharmacological, physical and 
neurotrophic treatments, with particular consid-
eration to ALA, that has the higher degree of ev-
idence among neurotrophic agents in neuropathic 
pain. We decided not to recommend a particular 
kind of pharmacological or physical treatment. 
The reason for this is that patients enrolled suf-
fered from different levels of pain (mild, moder-
ate or severe) and could be suffering from various 
comorbidities, thus a unique drug could not be 
recommended for all the patients. Furthermore, 
as regards physical therapies there is not a clear 
indication from literature and the participating 
centers could not have all the instruments for the 
various physical therapies available, so we decid-
ed to let the centers have freedom of choice in the 
pharmacological and physical treatments on the 
basis of patients’ characteristics.
In this investigation, we observed a clinically 
significant improvement in symptoms, disability 
and quality of life.
Key results of the study are in our opinion the 
general and considerable improvement in both 
perceived pain (NRS and BPI) and function-
al disability (RMDQ), that can be considered 
a remarkable result, considering that the most 
effective drugs used alone for neuropathic pain 
have a NRS pain reduction vs. placebo ranging 
Table V (Continued). SF-12 Health Survey Questionnaire at baseline and at the end of treatment. 
  Baseline  Final
11.		Have	you	felt	downhearted	and	depressed?    
 All of the time 9.3% 2.5%
 Most of the time 14% 3.8%
 A good bit of the time 20.5% 5.7%
 Some of the time 32.2% 28.9%
 A little of the time 19.3% 44.7%
 None of the time 4.7% 14.4%
12.	 During	the	past	4	weeks,	how	much	of	the	time	has	your	physical	health	or	emotional	problems	interfered	
	 with	your	social	activities	(like	visiting	friends,	relatives,	etc.)?
 All of the time 7.6% 2.5%
 Most of the time 19.9% 2.5%
 Some of the time 33.3% 7.5%
 A little of the time 31% 44.4%
 None of the time 8.2% 43.1%
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from -1.30 for gabapentin to -1.06 for duloxetine17. 
Furthermore, we observed a good adherence to 
the recommendation of the Study Group to adopt 
a multimodal strategy, with a greater prescription 
of all the three categories of treatments (neuro-
trophic, pharmacological and physical) in the 
patients with the higher levels of pain.
This report has several limitations, as it is an 
observational study which comprises a wide variety 
of treatments and can’t demonstrate the effective-
ness of a particular treatment or of an association of 
treatments. It can only suggest that the association 
of ALA with pharmacological and physical thera-
pies produce a clinically significant improvement 
in pain, functional disability and quality of life in 
patients suffering from LBP with sciatica. 
Another limitation is that, although the Study 
group recommended to include in the study only 
patients suffering from LBP with sciatica, a little 
percentage of the patients enrolled didn’t have a clear 
diagnosis of sciatic neuropathy. Despite this data, we 
considered all the patients included by the centers 
for the analysis, in the certainty that they all were 
endowed with a neuropathic component in LBP. 
Conclusions
This study describes a likely representative 
population of patients suffering from chronic 
LBP with sciatica whose conditions were care-
fully assessed by means of standardized and val-
idated questionnaires and followed prospectively 
for 2 months. Since a multimodal and multidisci-
plinary approach was adopted, a broad range of 
therapeutic options were used, which resulted in a 
general improvement in both perceived pain and 
functional disabilities. These results suggest that 
a multimodal approach can be beneficial in the 
treatment of LBP with sciatica.
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